Table 2.
Diagnostic Performance of Tetra- Antennary Markers at Site N241 for all HCC, Early HCC, and MASLDa
| all HCC (n = 59) vs cirrhosis (N = 60) |
early stage (N = 37) vs cirrhosis (N = 60) |
MASLD (N = 23) vs cirrhosis (N = 60) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| markers | AUC | 95% CI | p-value | AUC | 95% CI | p-value | AUC | 95% CI | p-value |
| a. Diagnostic Performance of Individual Markers at Site N241 for Al HCC, Early HCC, and MASLD | |||||||||
| AFP | 0.755 | (0.665,0.836) | <0.0001 | 0.739 | (0.632,0.838) | 0.0001 | 0.848 | (0.715,0.954) | 0.0001 |
| gender | 0.572 | (0.488,0.656) | 0.1320 | 0.558 | (0.456,0.650) | 0.2948 | 0.617 | (0.492,0.751) | 0.0955 |
| age | 0.695 | (0.595,0.782) | 0.0003 | 0.738 | (0.635,0.827) | 0.0001 | 0.624 | (0.45,0.792) | 0.1759 |
| A4G4F3S2 | 0.563 | (0.461,0.663) | 0.2360 | 0.552 | (0.438,0.665) | 0.3874 | 0.559 | (0.384,0.728) | 0.5174 |
| A4G4F1S3 | 0.631 | (0.522,0.731) | 0.0132 | 0.601 | (0.486,0.718) | 0.0959 | 0.502 | (0.335,0.684) | 0.9903 |
| A4G4F3S3 | 0.658 | (0.559,0.753) | 0.0030 | 0.667 | (0.553,0.777) | 0.0059 | 0.665 | (0.506,0.826) | 0.0660 |
| A4G4F2S4 | 0.573 | (0.472,0.674) | 0.1593 | 0.582 | (0.462,0.691) | 0.1706 | 0.574 | (0.404,0.748) | 0.4065 |
| b. Diagnostic Performance of Glycopeptide Markers at Site N241 in the Combination of AFP with All HCC, early HCC, and MASLD | |||||||||
| AFP | 0.755 | (0.665,0.836) | Reference | 0.739 | (0.632,0.838) | Reference | 0.848 | (0.715,0.954) | Reference |
| AFP + A4G4F3S2 | 0.796 | (0.718,0.870) | 0.5040 | 0.781 | (0.678,0.875) | 0.5658 | 0.841 | (0.698,0.957) | 0.9152 |
| AFP + A4G4F1S3 | 0.763 | (0.675,0.842) | 0.9114 | 0.743 | (0.633,0.845) | 0.9602 | 0.845 | (0.700,0.952) | 0.9565 |
| AFP + A4G4F3S3 | 0.766 | (0.686,0.846) | 0.8660 | 0.756 | (0.652,0.857) | 0.826 | 0.862 | (0.720,0.961) | 0.8890 |
| AFP + A4G4F2S4 | 0.802 | (0.723,0.877) | 0.4358 | 0.789 | (0.691,0.880) | 0.4888 | 0.836 | (0.693,0.945) | 0.8732 |
| c. Diagnostic Performance of Glycopeptide Markers at Site N241 in the Combination of Gender with All HCC, Early HCC, and MASLD | |||||||||
| AFP | 0.755 | (0.665,0.836) | Reference | 0.739 | (0.632,0.838) | Reference | 0.848 | (0.715,0.954) | Reference |
| Gender + A4G4F3S2 | 0.662 | (0.555,0.755) | 0.1592 | 0.634 | (0.515,0.75) | 0.1955 | 0.634 | (0.461,0.812) | 0.0439 |
| Gender + A4G4F1S3 | 0.602 | (0.495,0.709) | 0.0217 | 0.598 | (0.484,0.711) | 0.076 | 0.708 | (0.542,0.874) | 0.1671 |
| Gender + A4G4F3S3 | 0.614 | (0.511,0.718) | 0.0375 | 0.591 | (0.475,0.708) | 0.0707 | 0.684 | (0.514,0.853) | 0.1185 |
| Gender + A4G4F2S4 | 0.717 | (0.621,0.807) | 0.543 | 0.712 | (0.599,0.818) | 0.7214 | 0.746 | (0.587,0.889) | 0.3009 |
| d. Diagnostic Performance of Glycopeptide Markers at Site N241 in the Combination of Gender with All HCC, Early HCC, and MASLD | |||||||||
| AFP | 0.755 | (0.665,0.836) | Reference | 0.739 | (0.632,0.838) | Reference | 0.848 | (0.715,0.954) | Reference |
| Age + A4G4F3S2 | 0.718 | (0.618,0.806) | 0.5663 | 0.751 | (0.651,0.841) | 0.8743 | 0.621 | (0.447,0.8) | 0.0414 |
| Age + A4G4F1S3 | 0.712 | (0.616,0.805) | 0.5073 | 0.755 | (0.654,0.836) | 0.8285 | 0.622 | (0.447,0.797) | 0.0408 |
| Age + A4G4F3S3 | 0.704 | (0.602,0.793) | 0.4347 | 0.740 | (0.641,0.831) | 0.9925 | 0.626 | (0.452,0.807) | 0.0426 |
| Age + A4G4F2S4 | 0.736 | (0.631,0.823) | 0.7641 | 0.781 | (0.691,0.866) | 0.5603 | 0.657 | (0.493,0.816) | 0.0795 |